Matches in Wikidata for { <http://www.wikidata.org/entity/Q61314865> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q61314865 description "article scientifique publié en 1999" @default.
- Q61314865 description "artículu científicu espublizáu n'abril de 1999" @default.
- Q61314865 description "im April 1999 veröffentlichter wissenschaftlicher Artikel" @default.
- Q61314865 description "scientific article published on 01 April 1999" @default.
- Q61314865 description "wetenschappelijk artikel" @default.
- Q61314865 description "наукова стаття, опублікована у квітні 1999" @default.
- Q61314865 name "Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial" @default.
- Q61314865 name "Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial" @default.
- Q61314865 type Item @default.
- Q61314865 label "Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial" @default.
- Q61314865 label "Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial" @default.
- Q61314865 prefLabel "Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial" @default.
- Q61314865 prefLabel "Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial" @default.
- Q61314865 P1433 Q61314865-1973C3B2-CA00-4E77-BE84-34B18A2FA563 @default.
- Q61314865 P1476 Q61314865-A89201E7-22BE-4C78-9C8A-E54BDA93F5DF @default.
- Q61314865 P2093 Q61314865-3A00A0B2-B09F-462C-987E-B7F3F183B65D @default.
- Q61314865 P2093 Q61314865-43BA136A-F5E4-4D3F-9C85-9D0DDF9ADBEF @default.
- Q61314865 P2093 Q61314865-4EFB966B-59AC-4977-9B83-7AF53BAF329A @default.
- Q61314865 P2093 Q61314865-671A9CDE-DD00-41F3-BCFE-FF679EB9CB46 @default.
- Q61314865 P2093 Q61314865-84A72F64-EA22-4D0D-B4BD-069136B3C641 @default.
- Q61314865 P2093 Q61314865-87828D87-2253-476B-B816-3A95812303D1 @default.
- Q61314865 P2093 Q61314865-BE5CD54B-65B4-4107-9040-C75DB54D39EB @default.
- Q61314865 P2093 Q61314865-D1BF38CF-1990-410A-81F8-85B96BA1EC23 @default.
- Q61314865 P2093 Q61314865-DEA54701-983E-4C39-B1BF-31D2E69660B1 @default.
- Q61314865 P2093 Q61314865-F63ED84C-FCBE-414B-8AE0-32C878635280 @default.
- Q61314865 P2093 Q61314865-F9152022-1ABD-4BC2-AF4C-A529488F7CF0 @default.
- Q61314865 P2888 Q61314865-E3B954FB-1DBF-4968-BBBF-115D36BB773F @default.
- Q61314865 P304 Q61314865-18CB00C8-B642-4209-9115-5A3C0AEEBA10 @default.
- Q61314865 P31 Q61314865-3CF4AB7C-7BEE-456D-8201-DB8C982E7A91 @default.
- Q61314865 P356 Q61314865-61B4D7AC-FB45-49B0-830F-341C6A56FA6E @default.
- Q61314865 P433 Q61314865-B00ADB12-B005-470F-9864-DA5E5B58E04F @default.
- Q61314865 P478 Q61314865-0E923D6A-5651-41FC-81E1-2741B53D6969 @default.
- Q61314865 P50 Q61314865-01275610-7B01-4E2F-B5E6-59BE163F0ABB @default.
- Q61314865 P577 Q61314865-A9C03F8B-6FF4-4DC8-B635-F7C9F0823733 @default.
- Q61314865 P698 Q61314865-1B2458F9-848F-4BA7-8304-63978CAF496A @default.
- Q61314865 P921 Q61314865-0023A7D1-A2D2-4E9D-A89D-F02BA0530ECD @default.
- Q61314865 P921 Q61314865-0379A312-626B-4E8B-ACA3-6DF723A3B732 @default.
- Q61314865 P921 Q61314865-47de46c0-20e3-47c6-9af4-64d2bee74b47 @default.
- Q61314865 P356 S10434-999-0272-4 @default.
- Q61314865 P698 10340886 @default.
- Q61314865 P1433 Q2853069 @default.
- Q61314865 P1476 "Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group" @default.
- Q61314865 P2093 "A Peressini" @default.
- Q61314865 P2093 "C Semino" @default.
- Q61314865 P2093 "F Cafiero" @default.
- Q61314865 P2093 "G Melioli" @default.
- Q61314865 P2093 "G Pietra" @default.
- Q61314865 P2093 "I Ribizzi" @default.
- Q61314865 P2093 "M Gipponi" @default.
- Q61314865 P2093 "M Ponte" @default.
- Q61314865 P2093 "M R Sertoli" @default.
- Q61314865 P2093 "R Lionetto" @default.
- Q61314865 P2093 "S Vecchio" @default.
- Q61314865 P2888 s10434-999-0272-4 @default.
- Q61314865 P304 "272-278" @default.
- Q61314865 P31 Q13442814 @default.
- Q61314865 P356 "10.1007/S10434-999-0272-4" @default.
- Q61314865 P433 "3" @default.
- Q61314865 P478 "6" @default.
- Q61314865 P50 Q42645961 @default.
- Q61314865 P577 "1999-04-01T00:00:00Z" @default.
- Q61314865 P698 "10340886" @default.
- Q61314865 P921 Q1427096 @default.
- Q61314865 P921 Q194908 @default.
- Q61314865 P921 Q5452194 @default.